FDA-approved GLP-1 weight loss medication is generally safe for appropriate patients when prescribed and monitored by a qualified healthcare professional. It is not risk-free. The most common side effects are nausea, vomiting, diarrhea, constipation and abdominal discomfort. More serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, allergic reactions and complications during anesthesia.
In 2026, the FDA-approved options for weight management include Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide). These medications should be used at the prescribed dose, with increases made gradually. Compounded and unapproved GLP-1 products carry extra quality and dosing risks.
GLP-1 Medication Safety at a Glance
| Safety question | Practical answer |
|---|---|
| Are FDA-approved GLP-1 weight loss drugs safe? | Generally yes for appropriately selected patients under medical supervision |
| Most common side effects | Nausea, diarrhea, vomiting, constipation and abdominal pain |
| Important serious risks | Pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions and serious allergic reactions |
| Who should not use them? | People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a serious allergy to the medication |
| Pregnancy | Weight-loss treatment should be stopped when pregnancy is recognized. Semaglutide generally requires stopping at least two months before a planned pregnancy |
| Are compounded versions equally safe? | No. Compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before marketing |
| Do they require monitoring? | Yes, especially during dose increases and when the patient has diabetes, kidney disease, gallbladder disease or gastrointestinal problems |
What Are the Common Side Effects?
The most common side effects affect the digestive system. GLP-1 medications slow stomach emptying and affect appetite and digestion, so symptoms are often strongest after a dose increase.
Common side effects include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain or discomfort
- Bloating, burping or indigestion
- Acid reflux
- Fatigue
- Headache
In the STEP 1 trial of semaglutide for obesity, gastrointestinal events occurred more often with semaglutide than with placebo. Most were mild to moderate and temporary. About 4.5% of people taking semaglutide stopped treatment because of gastrointestinal events, compared with 0.8% of people taking placebo.
Gastrointestinal side effects were also the most common adverse events in the SURMOUNT-1 trial of tirzepatide. They occurred mainly during dose escalation and were usually mild to moderate.
Starting at a low dose and increasing it slowly can help limit side effects. Do not increase the dose faster than instructed.
What Serious Risks Should Patients Know About?
Pancreatitis
GLP-1 medications have been associated with reports of acute pancreatitis, or inflammation of the pancreas. Seek urgent medical advice for persistent or severe abdominal pain, especially when the pain spreads to the back or occurs with vomiting.
The prescribing information for Wegovy and Zepbound instructs clinicians to stop treatment if pancreatitis is suspected.
Gallstones and Gallbladder Disease
Rapid weight loss and GLP-1 treatment can be associated with gallstones, cholecystitis and other gallbladder problems. Symptoms may include persistent pain in the upper right abdomen, fever, jaundice, nausea or pain after eating.
Gallbladder problems occurred in clinical trials of semaglutide and tirzepatide, although reported rates were generally low.
Dehydration and Kidney Injury
Severe vomiting or diarrhea can cause dehydration. Dehydration can worsen kidney function, especially in people who already have kidney disease or take medicines that affect the kidneys.
Contact a healthcare professional if vomiting or diarrhea continues, you cannot keep fluids down, or you are urinating much less than usual. The FDA-approved labels for Wegovy and Zepbound warn about acute kidney injury related to volume depletion.
Severe Gastrointestinal Problems
Wegovy and Zepbound are not recommended for people with severe gastroparesis, a condition in which the stomach empties very slowly. Anyone with a history of serious digestive problems should discuss that history with the prescriber before starting treatment.
Low Blood Sugar
GLP-1 medications usually have a low risk of hypoglycemia when used alone. The risk increases when they are combined with insulin or medicines such as sulfonylureas that stimulate insulin release.
People taking insulin or a sulfonylurea may need medication adjustments and blood glucose monitoring. Do not change diabetes medication doses without medical advice.
Serious Allergic Reactions
Rare but serious allergic reactions, including anaphylaxis and angioedema, have been reported. Emergency symptoms include difficulty breathing, swelling of the face or throat, widespread hives, fainting or rapidly worsening symptoms.
Aspiration During Anesthesia or Deep Sedation
GLP-1 medications slow stomach emptying. Rare reports describe pulmonary aspiration during general anesthesia or deep sedation, even when standard fasting instructions were followed.
Tell the surgeon, anesthesiologist and other healthcare professionals that you take a GLP-1 medication before any planned procedure. Do not stop or continue the medication around surgery unless you have instructions from the medical team managing the procedure.
Is the Thyroid Cancer Warning a Reason to Avoid GLP-1 Drugs?
People with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2, should not use Wegovy or Zepbound.
Both medications carry a boxed warning because semaglutide and tirzepatide caused thyroid C-cell tumors in rodents. It is not known whether they cause medullary thyroid carcinoma in humans. The warning means prescribers should check the relevant personal and family history. It does not show that these medications cause thyroid cancer in people.
Report a neck lump, swelling, difficulty swallowing, difficulty breathing or persistent hoarseness to a healthcare professional.
Are GLP-1 Medications Safe During Pregnancy?
GLP-1 medications should not be used for weight loss during pregnancy. Wegovy's prescribing information states that the medication may cause fetal harm and should be discontinued when pregnancy is recognized. Semaglutide remains in the body for a prolonged period, so the label recommends stopping it at least two months before a planned pregnancy when it is being used for weight reduction.
Anyone who is pregnant, planning a pregnancy or breastfeeding should discuss treatment with an obstetrician or prescribing clinician before starting or continuing a GLP-1 medication.
Are Compounded GLP-1 Medications Safe?
Compounded semaglutide and tirzepatide are not automatically equivalent to FDA-approved products in safety, quality or effectiveness.
The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. The agency has received reports of dosing errors involving compounded injectable semaglutide, including cases that required medical attention or hospitalization. Problems can occur when patients measure doses from multidose vials, use unfamiliar syringes or follow incorrect titration instructions.
The FDA has also warned about:
- Products with inaccurate labels
- Fraudulent products marketed under the name of a pharmacy
- Semaglutide salt forms, such as semaglutide sodium or semaglutide acetate
- Doses that exceed the approved product label
- Products sold online as "research use only" or "not for human consumption"
If a compounded medication is medically necessary, obtain it through a licensed prescriber and a state-licensed pharmacy. Avoid products sold directly through unverified websites or social media.
Who May Need Extra Caution?
A clinician should review the risks and benefits carefully before prescribing a GLP-1 weight loss medication to someone with:
- A personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Severe gastroparesis or major gastrointestinal disease
- Previous pancreatitis
- Gallstones or gallbladder disease
- Kidney disease or frequent dehydration
- Diabetic retinopathy
- A history of serious allergic reactions to GLP-1 medications
- Pregnancy, a planned pregnancy or breastfeeding
- Treatment with insulin or sulfonylureas
- An upcoming operation or procedure requiring anesthesia or deep sedation
A history of pancreatitis does not automatically mean a person can never use a GLP-1 medication. It does require a personal discussion with a clinician because pancreatitis is a recognized safety concern.
Do GLP-1 Medications Cause Suicidal Thoughts?
The FDA's evaluation did not find evidence that GLP-1 receptor agonists cause suicidal thoughts or behavior. In 2026, the FDA requested removal of suicidal behavior and ideation warnings from the labels of Wegovy, Zepbound and Saxenda. Patients should still report new or worsening depression, suicidal thoughts or major changes in mood to a healthcare professional immediately.
How Can You Use a GLP-1 Medication More Safely?
- Use an FDA-approved product when possible.
- Obtain the medication through a licensed prescriber and pharmacy.
- Follow the dose-escalation schedule exactly.
- Do not combine Wegovy with another semaglutide product or another GLP-1 medication.
- Do not combine Zepbound with Mounjaro or another GLP-1 medication unless specifically directed by a clinician.
- Drink enough fluids, especially if nausea, vomiting or diarrhea occurs.
- Tell every healthcare professional about the medication before surgery or sedation.
- Ask about medication interactions, especially if you take insulin, sulfonylureas or oral medicines with a narrow therapeutic range.
- Seek prompt care for severe abdominal pain, persistent vomiting, dehydration, jaundice, difficulty breathing or facial swelling.
Bottom Line
FDA-approved GLP-1 weight loss medications are safe for many adults when prescribed for an appropriate medical reason and monitored correctly. Their benefits can outweigh their risks, especially for people with obesity or weight-related health conditions.
The main safety concerns are gastrointestinal side effects, gallbladder disease, pancreatitis, dehydration, medication interactions, pregnancy and specific thyroid cancer contraindications. The decision should depend on your medical history, current medications, treatment goals and access to follow-up care, not on weight loss results alone.